The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study ... use as a weight-loss ...

For this study, researchers analyzed U.S. federal research data in which people were asked about their GLP-1 prescriptions. Results showed that among people without diabetes, GLP-1 drug use rose ...

For the study, researchers analyzed the ... There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug Administration approved semaglutide for use as a weight ...

Specific drug trends: The use of semaglutide and tirzepatide, potent GLP-1 receptor agonists, has seen a substantial rise in recent years. Patient population: The study utilized data from 217,442 ...

Novo Nordisk's GLP-1 receptor ... alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the versatile drug class. The small, 48-subject study ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows. Not only is ...

"This large cohort study ... 0.83-1.25). "Because of GLP-1s' known side effect of pancreatitis, there's been some concern about links between GLP-1 use and pancreatic cancer. And this just shows ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by ... whether exenatide use was associated with ...